Table 1.
General characteristics of thrombotic APS patients and control subjects.
| Normal controls | APS patients | Thrombosis patients | AID patients | |
|---|---|---|---|---|
| N | 93 | 54 | 39 | 49 |
| Age (years) | 37 ± 7 | 48 ± 14 | 47 ± 13 | 46 ± 13 |
| Sex, n (% female) | 88 (95%) | 36 (64%) | 22 (56%) | 42 (86%) |
| Primary APS, n (%) | N/A | 52 (96%) | N/A | N/A |
| Secondary APS, n (%) | N/A | 2 (4%) | N/A | N/A |
| Lupus Anticoagulant, n (%) | N/A | 38 (70%) | 0 (0%) | 2 (4%) |
| anti-cardiolipin antibodies, n (%) | N/A | 32 (59%) | 0 (0%) | 4 (8%) |
| anti-β2GPI antibodies, n (%) | N/A | 34 (63%) | 0 (0%) | 5 (10%) |
| anti-PS/PT, n (%) | N/A | 32 (59%) | 3 (8%) | 6 (12%) |
| Thrombosis, n (%) | 0 (0%) | 54 (100%) | 39 (100%) | 0 (0%) |
| Arterial thrombosis, n (%) | 0 (0%) | 22 (41%) | 7 (18%) | 0 (0%) |
| Venous thrombosis, n (%) | 0 (0%) | 40 (74%) | 32 (82%) | 0 (0%) |
Age is shown as mean ± standard deviation and all other variables are shown as the number of subjects with the percentage of subjects between brackets. AID, auto-immune disease; APS, antiphospholipid syndrome.